(ANSA) - BRUSSELS, APRIL 07 - "Sometimes our language appears more complicated than it should be. What we have learned from the detailed case assessment is that there is a strong link between the AstraZeneca vaccine and rare side events" and for this reason there is a "probable cause between events and vaccine administration".
Lochiarisce the president of the Prac, the EMA's risk assessment commission, Sabine Straus to a request for declarations on the press release published by the Agency that speaks of "possible links".
"EMA's safety committee will mandate robust studies on AstraZeneca to understand more about the risk effects" of its vaccine.
This was stated by the head of the EMA data analysis task force, Peter Arlett, speaking at a press conference.
The Anglo-Swedish company will have to do "laboratory studies to try to better understand the effect of vaccines on coagulation, examine existing data from close clinical trials to assess whether there is more information on possible risks and also conduct epidemiological studies," Arlett pointed out.
(HANDLE).
